(E)-N'-((4-bromophenyl)sulfonyl)-N,N-dimethyl-formimidamide | 900814-23-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (E)-N'-((4-bromophenyl)sulfonyl)-N,N-dimethyl-formimidamide
• 英文别名: 4-bromo-N-[(1E)-(dirnethylamino)methylene]benzenesulfonamide；N,N-dimethyl-N'-(4-bromobenzenesulfonyl)formamidine；4-bromo-N-[1-dimethylaminomethylidene]benzenesulfonamide；N'-(4-bromophenyl)sulfonyl-N,N-dimethylmethanimidamide
• CAS: 900814-23-5
• 化学式: C₉H₁₁BrN₂O₂S
• 分子量: 291.169
• InChiKey: ALORMAUGCHGNLU-YRNVUSSQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  58.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (E)-N'-((4-bromophenyl)sulfonyl)-N,N-dimethyl-formimidamide 、 2-巯基乙醇 生成 4-((2-hydroxyethyl)thio)benzenesulfonamide
  参考文献：
  名称：

  SHEPARD, KENNETH L.

  摘要：

  DOI：
• 作为产物：
  描述：

  4-溴苯磺酰胺 、 N,N-二甲基甲酰胺二甲基缩醛 以 乙腈 为溶剂， 生成 (E)-N'-((4-bromophenyl)sulfonyl)-N,N-dimethyl-formimidamide
  参考文献：
  名称：

  Substituted benzenesulfonamides

  摘要：

  带有取代烷基-S(O).sub.n-取代基的苯磺酰胺是一种对抗高眼压治疗中有用的碳酸酐酶抑制剂。

  公开号：

  US04678855A1

文献信息

• Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use
  申请人：JAEHNE Gerhard

  公开号：US20090215728A1

  公开（公告）日：2009-08-27

  This invention relates to arylaminoaryl-alkyl-substituted imidazolidone-2,4-diones of formula (I) and also to their physiologically tolerated salts: Wherein R, R′, R1 to R10, A, D, E, G, L and p are as defined herein. The invention also relates to processes for preparing them, pharmaceutical compositions comprising them and their therapeutic use. The compounds are suitable, for example, as anti-obesity drugs and for treating cardiometabolic syndrome.

  这项发明涉及公式（I）中的芳基氨基芳基烷基取代的咪唑烷二酮及其生理耐受的盐： 其中R、R'、R1至R10、A、D、E、G、L和p如本文所定义。该发明还涉及制备它们的方法、包含它们的药物组合物以及它们的治疗用途。这些化合物适用于例如作为抗肥胖药物和治疗心脏代谢综合征。
• ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS
  申请人：MERCK SHARP & DOHME CORP.

  公开号：US20170275260A1

  公开（公告）日：2017-09-28

  The present disclosure relates to compounds of formula I that are useful as modulators of α7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation

  本公开涉及公式I的化合物，这些化合物可用作α7 nAChR的调节剂，包含这些化合物的组合物，以及利用这些化合物预防、治疗或改善疾病，特别是中枢神经系统疾病，如阿尔茨海默病、帕金森病和精神分裂症，以及L-多巴引起的运动障碍和炎症。
• Copper-catalyzed the coupling reaction of sulfonylazides with formamides for the synthesis of N-sulfonyl amidines
  作者：Guoyang Ma、Ran Xia、Yawen Li、Shaohong Xu

  DOI：10.1016/j.tet.2024.133869

  日期：2024.3

  A new strategy for copper-catalyzed the coupling reaction of sulfonylazides with formamides to construct a series of functionalized -sulfonyl amidines in moderate to excellent yields has been established. Diazo reagent was applied as an important additive to activate formamides. This methodology was distinguished by operational simplicity, easily available starting materials and good functionality

  建立了一种铜催化磺酰叠氮与甲酰胺偶联反应的新策略，以中等至优异的收率构建一系列功能化的磺酰脒。重氮试剂作为重要的添加剂用于活化甲酰胺。该方法的特点是操作简单、起始材料容易获得和良好的功能容差。
• Substituted benzenesulfonamide and antiglaucoma formulations containing them
  申请人：Merck & Co., Inc.

  公开号：EP0219429A1

  公开（公告）日：1987-04-22

  Benzenesulfonamides with a substituted-alkyl-S(O)n- substituent are carbonic anhydrase inhibitors useful in the treatment of elevated intra-ocular pressure.

  具有取代烷基-S(O)n-取代基的苯磺酰胺类药物是一种碳酸酐酶抑制剂，可用于治疗眼内压升高。
• Substituted bicyclic heteroaryl allosteric modulators of nicotinic acetylcholine receptors
  申请人：Merck Sharp & Dohme Corp.

  公开号：US10870630B2

  公开（公告）日：2020-12-22

  The present disclosure relates to compounds of formula (I) that are useful as modulators of α7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation.

  本公开涉及可用作α7 nAChR调节剂的式(I)化合物、包含此类化合物的组合物，以及使用此类化合物预防、治疗或改善疾病，特别是中枢神经系统疾病，如阿尔茨海默病、帕金森病和精神分裂症中的认知障碍，以及L-DOPA诱导的运动障碍和炎症。